Top

Journal of Gastrointestinal Surgery

Published in:

Open Access 01-05-2012 | Original Article

Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma

Authors: M. J. D. Prins, R. J. J. Verhage, F. J. W. ten Kate, R. van Hillegersberg

Published in: Journal of Gastrointestinal Surgery | Issue 5/2012

Abstract

Background

Cyclooxygenase isoenzyme-2 (COX-2) and vascular endothelial growth factor (VEGF) contribute to angiogenesis and are overexpressed in various malignancies. The aim of the study was to evaluate expression, prognostic value and correlation between COX-2 and VEGF expression in esophageal adenocarcinoma (EAC).

Methods

Surgical specimens of 154 patients with EAC were used to construct a tissue micro array (TMA). TMA sections were immunohistochemically stained for COX-2 and VEGF and scored on intensity of staining.

Results

Estimated 5-year cancer specific survival was 37%. High COX-2 and VEGF expression was observed in 39 (26.5%) and in 77 (53.8%) tumors, respectively. Both markers were associated with poor cancer specific survival (p = .022 and p = .004, respectively, log rank). No significant correlation was found between VEGF and COX-2 expression (r = 063; p = .455). In multivariate analysis, high COX-2 expression (HR 1.65; 95% CI 1.04–2.61; p = .034) was associated with overall survival. In patients with T3 tumors, COX-2 expression was an independent prognostic factor for cancer specific survival (HR 1.81 95% CI 1.10–2.95; p = .019).

Conclusions

This is the first study that evaluated the prognostic value and correlation of COX-2 and VEGF expression in a large and homogenous population of patients with EAC. No correlation between COX-2 and VEGF expression was found. Both markers were expressed in EAC and were associated with poor prognosis. The findings support the use of COX-2 and VEGF inhibitors in future clinical studies.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60:277–300.PubMedCrossRef

Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N.Engl.J.Med. 2006;355:11-20.PubMedCrossRef

Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, ten Kate FJW, Obertop H, Tilanus HW, Van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann.Surg. 2007;246:992–1000.PubMedCrossRef

van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br.J.Cancer 2006;94:1389–1394.PubMedCrossRef

Aklilu M, Ilson DH. Targeted agents and esophageal cancer--the next step? Semin.Radiat.Oncol. 2007;17:62–69.PubMedCrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.PubMedCrossRef

Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.PubMedCrossRef

Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 2008;14:8221–8227.PubMedCrossRef

Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 2000;6:519–525.PubMed

10.

Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, Visvanathan K, Goggins M. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol. Ther. 2007;6:1569–1575.PubMedCrossRef

11.

Wu YC, Su LJ, Wang HW, Jeff Lin CF, Hsu WH, Chou TY, Huang CY, Lu CL, Hsueh CT. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J.Thorac.Oncol. 2010;5:1167–1174.PubMedCrossRef

12.

Barisik NO, Keser SH, Gul AE, Sensu S, Kandemir NO, Kucuk HF, Gumus M, Karadayi N. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast. Med. Oncol. 2010;28:703–708.PubMedCrossRef

13.

Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IHM, ten Kate FJW. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis. Esophagus. 2009;22:496–504.PubMedCrossRef

14.

Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800–1807.PubMedCrossRef

15.

Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie. 2005;28:281–288.PubMedCrossRef

16.

Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010;116:4318–4325.PubMedCrossRef

17.

Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, Dubourg C, Lobel B, Denis M, Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 2009;101:1417–1424.PubMedCrossRef

18.

Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol. 2005;36:955–961.PubMedCrossRef

19.

Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L, Zhang Y. Clinicopathologic significance of HIF-1alpha, CXCR4, and VEGF expression in colon cancer. Clin. Dev. Immunol. 2010;2010:

20.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–1311.PubMed

21.

Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19:19–27.PubMedCrossRef

22.

Tuynman JB, Buskens CJ, Kemper K, ten Kate FJW, Offerhaus GJ, Richel DJ, Van Lanschot JJ. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 2005;242:840–9.PubMedCrossRef

23.

von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, Piontek G, Siewert JR, Hofler H, Sarbia M. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 2005;65:5038–5044.CrossRef

24.

Verhage RJ, Zandvoort HJ, ten Kate FJ, van Hillegersberg R. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am. J. Surg. Pathol. 2011;35:919–926.PubMedCrossRef

25.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual (7th edition). 2010

26.

Heeren P, Plukker J, van Dullemen H, Nap R, Hollema H. Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett. 2005;225:283–289.PubMedCrossRef

27.

Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di NF, Patel P. Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC.Cancer 2006;6:134.PubMedCrossRef

28.

Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Tamotsu K, Owaki T, Ishigami S, Aikou T. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur. J. Surg. Oncol. 2008;34:397–402.PubMed

29.

Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206–213.

30.

Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 2000;6:1161–1168.PubMed

31.

Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J. Surg. 2003;27:584–589.PubMedCrossRef

32.

Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF. Angiogenesis in the neoplastic sequence of Barrett’s oesophagus. Correlation with VEGF expression. J.Pathol. 2000;192:14–18.PubMedCrossRef

33.

Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK. Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas. J. Korean Med. Sci. 2002;17:201–207.PubMed

34.

Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis. Esophagus. 2003;16:112–118.PubMedCrossRef

35.

Lu CL, Ji Y, Ge D, Guo J, Ding JY. The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Dis. Esophagus. 2011;24:283–290.PubMedCrossRef

36.

Vallbohmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch. Surg. 2006;141:476–481.PubMedCrossRef

37.

Yoshikawa R, Fujiwara Y, Koishi K, Kojima S, Matsumoto T, Yanagi H, Yamamura T, Hashimoto-Tamaoki T, Nishigami T, Tsujimura T. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence. World J. Gastroenterol. 2007;13:2283–2288.PubMed

38.

Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR. COX2 expression, angiogenesis, proliferation and survival in Barrett’s cancer. Eur. J. Surg. Oncol. 2005;31:755–759.PubMed

39.

Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 1998;4:2195–2200.PubMed

40.

Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br. J. Cancer 1998;77:1704–1709.PubMedCrossRef

41.

Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br. J. Cancer 1999;80:1366–1372.PubMedCrossRef

42.

Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2003;129:430–436.PubMedCrossRef

43.

Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, Saclarides TJ. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am. Surg. 2000;66:401–405.PubMed

44.

Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J. Pathol. 2004;202:367–374.PubMedCrossRef

45.

Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res. Treat. 2005;89:215–220.PubMedCrossRef

46.

Sivula A, Buskens CJ, Van Rees BP, Haglund C, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int. J. Cancer 2005;116:903–908.PubMedCrossRef

47.

Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 2006;24:5201–5206.PubMedCrossRef

48.

Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB3. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 2010;28:2947–2951.PubMedCrossRef

49.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J. Clin. Oncol. 2011;29:868–874.PubMedCrossRef

50.

Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, Zalcberg JR. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007;25:123–129.PubMedCrossRef

51.

Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, Hanna N, Stoner C, Ansari R, Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston.Park) 2004;18:18-21.

52.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N.Engl.J.Med. 2005;352:1071-1080.PubMedCrossRef

Title: Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma
Authors: M. J. D. Prins
R. J. J. Verhage
F. J. W. ten Kate
R. van Hillegersberg
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 5/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1814-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Limitations of Patient-Associated Co-Morbidity Model in Predicting Postoperative Morbidity and Mortality in Pancreatic Operations

Duodenum–Stomach Anastomosis: a New Technique for Exocrine Drainage in Pancreas Transplantation

Symptoms Resolution Post-Cholecystectomy: Patient Selection is Very Important

Enteral Nutrition Reduces Delayed Gastric Emptying After Standard Pancreaticoduodenectomy with Child Reconstruction

After Distal Pancreatectomy Pancreatic Leakage from the Stump of the Pancreas May Be Due to Drain Failure or Pancreatic Ductal Back Pressure

CIP2A Is a Predictor of Poor Prognosis in Colon Cancer